Chardan Capital Weighs in on MeiraGTx FY2026 Earnings

MeiraGTx Holdings plc (NASDAQ:MGTX) – Research analysts at Chardan Capital issued their FY2026 earnings estimates for shares of MeiraGTx in a report released on Monday, March 24th. Chardan Capital analyst D. Gataulin forecasts that the company will post earnings per share of ($1.09) for the year. Chardan Capital currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for MeiraGTx’s current full-year earnings is ($1.48) per share.

Separately, Royal Bank of Canada upped their price target on MeiraGTx from $11.00 to $13.00 and gave the stock an “outperform” rating in a report on Monday, March 17th.

MeiraGTx Price Performance

MGTX stock opened at $7.39 on Thursday. The firm has a market cap of $582.74 million, a P/E ratio of -6.11, a price-to-earnings-growth ratio of 0.37 and a beta of 1.23. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.34 and a current ratio of 2.34. MeiraGTx has a 1 year low of $3.85 and a 1 year high of $8.75. The stock has a 50-day simple moving average of $6.81 and a 200-day simple moving average of $6.03.

MeiraGTx (NASDAQ:MGTX) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The company had revenue of $21.39 million during the quarter, compared to analyst estimates of $1.50 million. MeiraGTx had a negative net margin of 633.05% and a negative return on equity of 146.38%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Janney Montgomery Scott LLC bought a new position in MeiraGTx during the fourth quarter worth $459,000. Barclays PLC raised its holdings in shares of MeiraGTx by 107.1% during the third quarter. Barclays PLC now owns 147,827 shares of the company’s stock worth $618,000 after purchasing an additional 76,437 shares during the period. State Street Corp lifted its position in shares of MeiraGTx by 0.9% in the 3rd quarter. State Street Corp now owns 574,727 shares of the company’s stock worth $2,397,000 after buying an additional 5,251 shares during the last quarter. Garden State Investment Advisory Services LLC acquired a new position in shares of MeiraGTx in the 3rd quarter valued at about $1,636,000. Finally, JPMorgan Chase & Co. grew its position in shares of MeiraGTx by 1.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 342,667 shares of the company’s stock valued at $1,429,000 after buying an additional 4,186 shares during the last quarter. Institutional investors and hedge funds own 67.48% of the company’s stock.

Insiders Place Their Bets

In other MeiraGTx news, CFO Richard Giroux sold 24,000 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.29, for a total transaction of $150,960.00. Following the transaction, the chief financial officer now directly owns 849,947 shares in the company, valued at $5,346,166.63. This represents a 2.75 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Alexandria Forbes sold 35,839 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $6.47, for a total transaction of $231,878.33. Following the transaction, the chief executive officer now directly owns 1,395,102 shares in the company, valued at $9,026,309.94. The trade was a 2.50 % decrease in their position. The disclosure for this sale can be found here. 8.40% of the stock is currently owned by company insiders.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.